Drug Profile
Dicycloplatin
Alternative Names: DCPLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Peking University
- Developer Sopo-Xingda Pharmaceutical
- Class Antineoplastics; Platinum complexes; Small molecules
- Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Non-small cell lung cancer
Most Recent Events
- 16 Feb 2016 No development reported - Phase-II for Non-small cell lung cancer (Combination therapy, First-line therapy) in China (IV)
- 16 Feb 2016 No development reported - Registered for Cancer in China (IV)
- 23 Oct 2013 Pharmacodynamics data from a Preclinical trial and pharmacokinetics data from a Clinical trial presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2013)